Institutional shares held 130 Million
1.31M calls
1.56M puts
Total value of holdings $14.7B
$149M calls
$177M puts
Market Cap $244B
2,151,000,064 Shares Out.
Institutional ownership 6.04%
# of Institutions 1,503


Latest Institutional Activity in NVS

Top Purchases

Q1 2025
Scharf Investments, LLC Shares Held: 1.26M ($143M)
Q1 2025
Greenup Street Wealth Management LLC Shares Held: 41.1K ($4.67M)
Q1 2025
Garland Capital Management Inc Shares Held: 38.5K ($4.37M)
Q1 2025
Cerity Partners LLC Shares Held: 337K ($38.3M)
Q1 2025
Eldred Rock Partners, LLC Shares Held: 80.8K ($9.17M)

Top Sells

Q1 2025
Gamma Investing LLC Shares Held: 6.52K ($740K)
Q1 2025
Envestnet Asset Management Inc Shares Held: 1.61M ($183M)
Q1 2025
Mirae Asset Global Investments Co., Ltd. Shares Held: 428K ($48.6M)
Q1 2025
D.A. Davidson & Co. Shares Held: 399K ($45.3M)
Q1 2025
Chevy Chase Trust Holdings, Inc. Shares Held: 1.1M ($125M)

About NVS

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.


Insider Transactions at NVS

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
0 Shares
From 0 Insiders
Sell / Disposition
0 Shares
From 0 Insiders

Track Institutional and Insider Activities on NVS

Follow NOVARTIS AG and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells NVS shares.

Notify only if
Any

Insider Trading

Get notified when an Novartis Ag insider buys or sells NVS shares.

Notify only if
Any
Any
P - Open market or private purchase×
S - Open market or private sale×
V - Transaction voluntarily reported earlier than required×
A - Grant, award, or other acquisition×
D - Sale (or disposition) back to the issuer×
F - Payment of exercise price or tax liability×
I - Discretionary transaction×
M - Exercise of conversion of derivative security×
C - Conversion of derivative security×
E - Expiration of short derivative position×
H - Expiration (or cancellation) of long derivative position with value received×
O - Exercise of out-of-the-money derivative securities×
X - Exercise of in-the-money or at-the-money derivatives securities×
G - Bona fide gift×
L - Small Acquisition×
W - Acquisition or disposition by will or laws×
Z - Deposit into or withdrawal from voting trust×
J - Other acquisition or disposition×
K - Transaction in equity swap or similar instrument×
U - Disposition due to a tender of shares in a change of control transaction×
20 item(s) selected

News

Receive news related to NOVARTIS AG

Track Activities on NVS